GlassScriptPhysician profile
Curtis Robert Chong
NPI 1912167420
$99,002.31
in general payments reported to CMS, 2019-2025
38 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $25K · 2021: $1,493 · 2022: $1,316 · 2023: $44K · 2024: $3,667 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Consulting Fee: $7,300 · Food and Beverage: $326 · Honoraria: $200 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,862.00 |
| Consulting Fee | $7,299.50 |
| Food and Beverage | $326.28 |
| Honoraria | $200.00 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $86,761.08 | 2019-2023 | Foundationone Liquid Cdx, Foundationone Cdx |
| Astrazeneca Pharmaceuticals LP | $4,332.07 | 2019-2025 | Lynparza, Imfinzi |
| Vertex Pharmaceuticals Incorporated | $1,050.00 | 2021-2022 | |
| Beigene USA, INC. | $1,016.67 | 2022-2024 | |
| Genzyme Corporation | $864.08 | 2019-2021 | |
| Glaxosmithkline, LLC. | $601.45 | 2020-2022 | |
| Lantheus Medical Imaging, INC. | $550.00 | 2023 | |
| Becton, Dickinson and Company | $508.33 | 2023 | |
| Beigene, LTD. | $500.00 | 2023 | Brukinsa |
| Tersera Therapeutics LLC | $452.00 | 2025 | Margenza |
| Halozyme INC | $380.00 | 2024 | |
| Dr.Reddy'S Laboratories,INC. | $260.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $250.00 | 2022 | |
| Daiichi Sankyo INC. | $223.12 | 2019-2023 | |
| Leica Microsystems INC. | $213.00 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $147.40 | 2019-2021 | |
| Pfizer INC. | $139.65 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Celgene Corporation | $86.77 | 2025 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $59.38 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $44.08 | 2019-2020 | |
| Seagen INC. | $42.93 | 2019 | |
| Eisai INC. | $41.41 | 2019 | |
| Astellas Pharma US INC | $30.49 | 2025 | Vyloy |
| Adc Therapeutics America, INC. | $25.61 | 2025 | |
| Amgen INC. | $23.47 | 2019 | |
| Abbvie INC. | $22.38 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $22.13 | 2019 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Genentech USA, INC. | $20.29 | 2021 | |
| Lilly USA, LLC | $19.57 | 2019 | |
| Merck Sharp & Dohme LLC | $19.32 | 2021 | |
| Dova Pharmaceuticals | $19.21 | 2019 | |
| Kyowa Kirin, INC. | $17.17 | 2019 | |
| Kite Pharma, INC. | $14.07 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Chong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.